• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Medtronic Board appoints Dr. Joon Lee as a new director

    6/23/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MDT alert in real time by email

    GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board.

    "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with decades of broad leadership across healthcare. He is passionate about leveraging data and technology to improve the patient and provider experience—insights that will help us further our Mission to alleviate pain, restore health, and extend life for patients around the world."

    In his current role as CEO of Emory Healthcare, Inc., Dr. Lee oversees the most comprehensive academic health system in Georgia, with $7.7B in yearly revenue, 12 hospitals, and more than 29,000 employees.

    Dr. Lee's distinguished career spans more than 25 years at the University of Pittsburgh Medical Center (UPMC), where he held pivotal roles, including Executive Vice President and President of Physician Services. There, his scope included physician services, patient experience, patient access and financial oversight of physician services. He also served as Vice Dean of Clinical Affairs at the University of Pittsburgh School of Medicine.

    Additionally, Dr. Lee served as Chief of the Division of Cardiology and was the founding executive director of the UPMC Heart and Vascular Institute. From 2019 to 2021, Dr. Lee was the Chief Medical Officer of UPMC Insurance Services, a $13 billion full-service health insurance division of UPMC.

    Dr. Lee is certified in cardiovascular disease by the American Board of Internal Medicine. He is a fellow in the American College of Cardiology and Society for Coronary Angiography and Interventions. He completed a medical internship and residency, as well as two cardiology fellowships in cardiology and interventional cardiology, at Massachusetts General Hospital in Boston. In addition, he was an instructor at Harvard Medical School. He is a graduate of Dartmouth College (BA) and Duke University (MD).

    About Medtronic

    Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

    Contacts:



    Erika Winkels

     Ryan Weispfenning

    Public Relations

    Investor Relations

    +1-612-558-8932

    +1-763-505-4626

     

    (PRNewsfoto/Medtronic plc)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-board-appoints-dr-joon-lee-as-a-new-director-302488605.html

    SOURCE Medtronic plc

    Get the next $MDT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDT

    DatePrice TargetRatingAnalyst
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    6/16/2025$110.00Outperform
    Leerink Partners
    3/4/2025$92.00 → $107.00Neutral → Buy
    Citigroup
    10/10/2024$98.00 → $105.00Sector Perform → Outperform
    RBC Capital Mkts
    8/21/2024$92.00 → $94.00Perform
    Oppenheimer
    8/15/2024$76.00 → $90.00Sell → Neutral
    UBS
    8/14/2024$100.00 → $85.00Buy → Hold
    Stifel
    5/30/2024$83.00Sell
    Goldman
    More analyst ratings

    $MDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Blomquist Denise L. gifted 310 units of Ordinary Shares, decreasing direct ownership by 3% to 10,143 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      6/4/25 4:30:34 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • New insider Kiil Harry Skip claimed ownership of 33,442 units of Ordinary Shares (SEC Form 3)

      3 - Medtronic plc (0001613103) (Issuer)

      6/4/25 4:29:12 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 34 units of Ordinary Shares, decreasing direct ownership by 0.13% to 26,054 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      5/5/25 4:10:23 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    Leadership Updates

    Live Leadership Updates

    See more
    • Medtronic Board appoints Dr. Joon Lee as a new director

      GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

      6/23/25 4:15:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

      NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

      3/31/25 4:21:30 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

      Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe

      2/5/25 8:00:00 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products